Tapan Kadia Selected Research

Doxorubicin (Adriamycin)

2/2016	Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia.
5/2015	Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Tapan Kadia Research Topics

Disease

64	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 10/2022 - 08/2010
23	Neoplasms (Cancer) 10/2022 - 08/2011
23	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 10/2021 - 01/2012
18	Leukemia 10/2022 - 08/2010
17	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 09/2022 - 06/2014
17	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2022 - 01/2010
16	Philadelphia Chromosome 09/2022 - 02/2009
8	Primary Myelofibrosis (Myelosclerosis) 11/2021 - 08/2012
8	Residual Neoplasm 01/2021 - 02/2016
6	Acute Promyelocytic Leukemia 01/2022 - 06/2011
6	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2022 - 06/2012
5	Anemia 01/2022 - 08/2009
5	Chromosome Aberrations (Chromosome Abnormalities) 01/2022 - 06/2011
4	Thrombocytopenia (Thrombopenia) 01/2022 - 01/2018
4	Exanthema (Rash) 01/2021 - 11/2015
4	Blast Crisis (Blast Phase) 01/2021 - 08/2012
4	Hematologic Neoplasms (Hematological Malignancy) 01/2021 - 02/2012
4	Pathologic Complete Response 09/2019 - 05/2015
3	Lymphoma (Lymphomas) 01/2022 - 06/2012
3	Infections 01/2022 - 11/2015
3	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2022 - 07/2012
2	Leukocytosis (Pleocytosis) 01/2022 - 01/2017
2	Hypertension (High Blood Pressure) 12/2020 - 11/2015
2	Fatigue 09/2019 - 11/2018
2	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 01/2018 - 04/2016
2	Chronic Myelomonocytic Leukemia (Leukemia, Chronic Myelomonocytic) 01/2017 - 04/2014
2	Diarrhea 01/2016 - 06/2014
2	Nausea 01/2016 - 01/2015
2	Refractory Anemia with Excess of Blasts (RAEM) 10/2014 - 10/2013
2	Myeloid Leukemia (Leukemia, Myelocytic) 02/2013 - 07/2012
1	Invasive Fungal Infections 10/2022
1	Pneumonia (Pneumonitis) 01/2022
1	Hyperuricemia 01/2022
1	Hyperbilirubinemia 01/2022

Drug/Important Bio-Agent (IBA)

15	Tyrosine Kinase InhibitorsIBA 09/2022 - 08/2011
14	venetoclaxIBA 10/2022 - 10/2016
14	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2021 - 08/2010
12	Azacitidine (5 Azacytidine)FDA Link 01/2022 - 06/2013
10	Decitabine FDA Link 01/2022 - 09/2012
7	Inotuzumab OzogamicinIBA 01/2022 - 03/2015
7	Proteins (Proteins, Gene)FDA Link 01/2022 - 07/2012
6	Core Binding Factors (Core-Binding Factor)IBA 01/2022 - 08/2010
6	ruxolitinibIBA 11/2021 - 08/2012
6	Imatinib Mesylate (Gleevec)FDA Link 01/2020 - 01/2010
5	Sorafenib (BAY 43-9006)FDA Link 11/2020 - 06/2013
5	Dasatinib (BMS 354825)FDA Link 11/2020 - 08/2011
5	Arsenic Trioxide (Trisenox)FDA Link 09/2019 - 05/2015
5	Idarubicin (4 Demethoxydaunorubicin)FDA LinkGeneric 09/2019 - 11/2013
5	Tretinoin (Retinoic Acid)FDA LinkGeneric 09/2019 - 05/2015
5	Clofarabine (Clolar)FDA Link 02/2017 - 09/2012
4	blinatumomabIBA 09/2022 - 10/2018
4	ibrutinibIBA 12/2021 - 01/2019
4	Cyclophosphamide (Cytoxan)FDA LinkGeneric 12/2021 - 06/2014
4	Vascular Endothelial Growth Factor Receptor-1 (fms-Like Tyrosine Kinase)IBA 01/2021 - 12/2012
4	Vincristine (Oncovin)FDA LinkGeneric 01/2020 - 05/2015
4	nilotinib FDA Link 11/2016 - 01/2010
3	Lenalidomide (CC 5013)FDA Link 10/2022 - 01/2015
3	fludarabineIBA 12/2021 - 08/2010
3	Rituximab (Mabthera)FDA Link 12/2021 - 01/2019
3	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 11/2021 - 01/2019
3	ponatinibIBA 01/2021 - 11/2015
3	Agammaglobulinaemia Tyrosine KinaseIBA 01/2021 - 01/2019
3	Biological ProductsIBA 01/2021 - 09/2013
3	midostaurinIBA 11/2019 - 04/2015
3	Hemoglobins (Hemoglobin)IBA 09/2019 - 09/2014
3	Phosphotransferases (Kinase)IBA 06/2018 - 08/2015
3	Gemtuzumab (Mylotarg)FDA Link 02/2017 - 08/2010
3	Histone Deacetylase InhibitorsIBA 01/2012 - 08/2010
2	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2022 - 08/2015
2	CreatinineIBA 01/2022 - 01/2022
2	fms-Like Tyrosine Kinase 3IBA 01/2021 - 08/2012
2	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 01/2021 - 02/2017
2	MethyltransferasesIBA 01/2021 - 01/2019
2	Monoclonal AntibodiesIBA 01/2021 - 03/2015
2	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 11/2020 - 08/2010
2	nelarabine (506U78)FDA Link 11/2020 - 01/2018
2	NucleophosminIBA 10/2019 - 01/2019
2	NivolumabIBA 09/2019 - 01/2019
2	Transaminases (Aminotransferases)IBA 01/2018 - 06/2014
2	Janus KinasesIBA 01/2017 - 03/2015
2	Doxorubicin (Adriamycin)FDA LinkGeneric 02/2016 - 05/2015
2	Dexamethasone (Maxidex)FDA LinkGeneric 02/2016 - 05/2015
2	Alanine Transaminase (SGPT)IBA 01/2016 - 11/2015
2	Prednisone (Sone)FDA LinkGeneric 11/2015 - 09/2014
2	Aurora KinasesIBA 08/2015 - 06/2014
2	pomalidomideIBA 09/2014 - 11/2013
2	NucleosidesIBA 06/2014 - 11/2013
2	Vorinostat FDA Link 10/2010 - 08/2010
2	mocetinostatIBA 10/2010 - 08/2010
2	obatoclaxIBA 10/2010 - 08/2010
1	TriazolesIBA 10/2022

Therapy/Procedure

50	Therapeutics 10/2022 - 01/2010
30	Drug Therapy (Chemotherapy) 10/2022 - 11/2010
9	Induction Chemotherapy 01/2022 - 08/2010
7	Stem Cell Transplantation 01/2022 - 06/2011
3	Radiotherapy 10/2022 - 02/2012
3	Salvage Therapy 01/2021 - 01/2020
2	Drug Tapering 11/2021 - 11/2020
2	Consolidation Chemotherapy 01/2020 - 01/2018
1	Remission Induction 10/2022